23andMe to expand with $200M in latest funding round

23andMe, a Mountain View, Calif.-based personal genomics and biotechnology company, raised almost $200 million in an ongoing funding round, sources close to the matter told TechCrunch.

The funding round, which is reportedly at a $1.5 billion pre-money valuation, is led by Sequoia Capital. 23andMe will likely use the funds to expand its genetics research arm, according to TechCrunch. Although the Food and Drug Administration ordered the company to cease sales of its genomics tests in 2013, the agency began approving its updated products for select diseases in 2015.

23andMe and Sequoia declined TechCrunch's request for comment.

More articles on data analytics & precision medicine:
Kalorama: Apple, Google, IBM make waves in healthcare analytics market
Intermountain, U of Utah Health to develop EHR clinical decision support under $3.8M NCI grant
University of Rochester Medical Center taps NextGate to aggregate provider data

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months